0001415889-20-000125.txt : 20200117
0001415889-20-000125.hdr.sgml : 20200117
20200117165607
ACCESSION NUMBER: 0001415889-20-000125
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20200117
DATE AS OF CHANGE: 20200117
EFFECTIVENESS DATE: 20200117
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: AzurRx BioPharma, Inc.
CENTRAL INDEX KEY: 0001604191
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-358472
FILM NUMBER: 20534149
BUSINESS ADDRESS:
STREET 1: 760 PARKSIDE AVENUE
STREET 2: SUITE 304
CITY: BROOKLYN
STATE: NY
ZIP: 11226
BUSINESS PHONE: 646-699-7855
MAIL ADDRESS:
STREET 1: 760 PARKSIDE AVENUE
STREET 2: SUITE 304
CITY: BROOKLYN
STATE: NY
ZIP: 11226
FORMER COMPANY:
FORMER CONFORMED NAME: BioPharma d'Azur, Inc.
DATE OF NAME CHANGE: 20140331
D
1
primary_doc.xml
X0708
D
LIVE
0001604191
AzurRx BioPharma, Inc.
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
646-699-7855
DELAWARE
None
BioPharma d'Azur, Inc.
Corporation
true
Daniel
Schneiderman
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Executive Officer
Edward
Borkowski
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Director
Alastair
Riddell
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Director
James
Sapirstein
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Executive Officer
Director
Charles
Casamento
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Director
Vern
Schramm
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Director
James
Pennington
760 Parkside Ave.
Suite 304
Brooklyn
NY
NEW YORK
11226
Executive Officer
Biotechnology
No Revenues
- 06b
false
2019-12-20
false
true
true
false
10000
Alexander Capital, L. P.
40077
None
None
17 State Street
5th Floor
New York
NY
NEW YORK
10004
AR
ARKANSAS
CA
CALIFORNIA
CO
COLORADO
CT
CONNECTICUT
FL
FLORIDA
GA
GEORGIA
IL
ILLINOIS
MD
MARYLAND
MA
MASSACHUSETTS
NJ
NEW JERSEY
NY
NEW YORK
NC
NORTH CAROLINA
PA
PENNSYLVANIA
RI
RHODE ISLAND
SC
SOUTH CAROLINA
TX
TEXAS
WI
WISCONSIN
8000000
6904000
1096000
Offering completed on January 9, 2020.
false
0
70
553860
0
In addition, Alexander Capital, L.P. received a 1% non-accountable expense allowance from gross proceeds from the Offering, or $61,540, and was issued warrants exercisable for 444,104 shares of common stock, at an exercise price of $1.21 per share.
0
AzurRx BioPharma, Inc.
/s/ Daniel Schneiderman
Daniel Schneiderman
Chief Financial Officer
2020-01-17